nature neuroscience r e v i e w Human induced pluripotent stem cells (iPSCs) are derived by expressing pluripotency genes in differentiated adult somatic cells. This reprograms the cells back in time to an embryonic-like pluripotent state 1-3 . These pluripotent cells can then be differentiated into almost any cell type of the human body. Furthermore, when taken from patients with specific neurological disorders, the cells can be used to create powerful 'disease in a dish' models that recapitulate certain disease phenotypes. Corticospinal upper motor neurons (UMNs) and spinal cord lower motor neurons (LMNs) specifically degenerate in motor neuron diseases such as ALS. This unexplained motor neuron (MN) wasting results in paralysis and death, normally within 4 years of disease onset. Apart from one drug, riluzole, that extends lifespan by approximately 3 months, there are no treatments for this disease.
r e v i e w Human induced pluripotent stem cells (iPSCs) are derived by expressing pluripotency genes in differentiated adult somatic cells. This reprograms the cells back in time to an embryonic-like pluripotent state [1] [2] [3] . These pluripotent cells can then be differentiated into almost any cell type of the human body. Furthermore, when taken from patients with specific neurological disorders, the cells can be used to create powerful 'disease in a dish' models that recapitulate certain disease phenotypes. Corticospinal upper motor neurons (UMNs) and spinal cord lower motor neurons (LMNs) specifically degenerate in motor neuron diseases such as ALS. This unexplained motor neuron (MN) wasting results in paralysis and death, normally within 4 years of disease onset. Apart from one drug, riluzole, that extends lifespan by approximately 3 months, there are no treatments for this disease.
Recent studies generating MNs from ALS patients' iPSCs have revealed specific disease-relevant phenotypes, thereby validating the use of this system to explore the molecular underpinnings of ALS and to develop new screening platforms for drug development 4 . However, certain key challenges still remain: namely, which criteria to use to identify MNs at different stages in development, how to compare the many existing protocols for LMN differentiation, how to establish directed UMN differentiation strategies, and how to properly mature MNs in vitro. This Review summarizes the current status for generation of MNs from iPSCs for investigators interested in the basic biology and ultimate treatment of MN-based diseases.
Generating LMNs from pluripotent stem cells LMNs are a highly studied neuronal subtype because they are critical in activating skeletal muscle. Protocols for directing pluripotent stem cells (PSCs) toward LMNs are built on extensive neural specification studies conducted in amphibian, chick and mouse embryos [5] [6] [7] (reviewed by Jessell 8 , Kanning et al. 9 and Stifani 10 ). During gastrulation (Fig. 1a, panel 1 ), ectodermal cells are initially fated along the anterior-posterior axis by activation of fibroblast growth factors (FGFs) and Wingless-type MMTV integration site family members (Wnts) (Fig. 1a, panel 2 ). The neuroectoderm is specified (Fig. 1a,  panel 3 ) by inhibition of mesoderm and endoderm differentiation factors; namely, bone morphogenic proteins (BMPs) and transforming growth factor-β (TGFβ). Because the mere inhibition of alternative signaling pathways (for example, BMP and activin or TGFβ) is sufficient for neural induction, neural fate is seemingly the default path of embryonic differentiation 11, 12 . As the neuroectoderm is specified, signaling gradients act as positional cues to establish rostrocaudal and dorsoventral neural axes 13 . Presomitic mesoderm cells surrounding the spinal cord express aldehyde dehydrogenase 1 family, member A2 (Aldh1a2), an enzyme that synthesizes retinoic acid (Fig. 1a, panel 4) . Retinoic acid induces caudal neuronal subtypes of the hindbrain and rostral spinal cord and further directs neurogenesis. Retinoic acid signaling decreases caudally down the spinal cord, as indicated by both decreased expression of Aldh1a2 and increased inhibitory activity of FGFs, namely FGF8, which are highly expressed in the lumbar spinal cord and tail bud 14 . In addition to retinoic acid and FGFs, Wnts are also required for the induction of caudal hindbrain and spinal cord identities 15 . Another key molecule is the signaling protein Sonic Hedgehog (SHH), which determines dorsoventral spinal identity and is secreted from the notochord in r e v i e w a ventral gradient along the ventrodorsal axis (Fig. 1a, panel 5 ) 16 . High SHH concentrations have been shown to promote ventral spinal subtypes and are critical for MN induction 17 .
In seminal studies, these developmental signaling molecules were used to guide mouse embryonic stem (mES) cells into MNs in vitro 18 . mES cells were induced to differentiate by withdrawing leukemia inhibitory factor, a mitogen, and cultured as self-organizing suspended cellular aggregates referred to as embryoid bodies. By exposing mES cells to retinoic acid and SHH in the presence of knockout serum, which is a proprietary, partial purification of albumin from bovine serum, embryoid bodies were directed to a LMN fate. In human ES cells, the same developmental principle was followed, taking into account that, even in vitro, human cells inherently follow a much slower rate of development. Human ES cells were first differentiated to embryoid bodies and then into primitive neural stem cells in the absence of morphogens 19, 20 . This was followed by treatment with retinoic acid and SHH to induce ventral spinal progenitors before they became postmitotic MNs 21 . While these protocols showed promise and have been widely used, they were long, expensive and inefficient.
Enhanced LMN generation in vitro
A key breakthrough came with the discovery by Chambers et al. 22 that inhibition of BMP and TGFβ signaling by the small molecules SB431542 and LDN193189 early during PSC differentiation selectively blocks endodermal and mesodermal cell fates. This induced default neural specification, termed dual-SMAD inhibition, dramatically enriches neural ectoderm directly from pluripotent cells, as indicated by a high percentage of neural progenitors expressing paired box protein 6 (Pax6) and sex determining region Y-box 2 (Sox2) in embryonic stem cell and iPSC cultures (Fig. 1b, panel 3) . Early Pax6 and Sox2 enrichment in turn intrinsically represses alternative mesoderm and endoderm fates, thereby substantially reducing the length of differentiation protocols and, critically, the appearance of non-neuronal cell types.
Drawing from these discoveries, most differentiation protocols for human embryonic and iPSC-derived LMNs (referred to hereafter as hPSC-LMNs) share three fundamental steps in induction: neuralization through dual-SMAD inhibition, caudalization through retinoic acid exposure and ventralization through SHH activation by recombinant SHH protein or small molecule SHH activators (smSHHs). Of note, smSHHs potentially bypass feedback mechanisms related to SHH itself, including observed upregulation of Patched and the SHH binding protein Hhip 23 . The downstream consequences in neuronal differentiation between smSHHs and recombinant SHH have yet to be compared in vitro. Beyond these common patterning principles, the recent protocols for MN induction from PSCs are described below ( Fig. 2) [24] [25] [26] [27] [28] and show that even subtle in vitro differences in timing, plating and medium composition can strongly influence MN yield, purity and phenotype.
Until recently, the caudalization and ventralization phases of human MN differentiation had not been systematically improved over general retinoic acid and SHH administration. This resulted in inefficient yields of human MNs compared to those obtained in mES cell protocols. By altering the concentration, order and timing of the retinoic acid, Wnt3a, FGF2 and SHH signals during differentiation in vitro, Maury et al. 25 revealed a previously underappreciated role of graded Wnt signaling in MN development. Wnt activation with the glycogen synthase kinase 3 inhibitor CHIR-99021 results in up to 80% of cells expressing the oligodendrocyte transcription factor Olig2, a marker for MN progenitor cells (Fig. 1b, panel 2) . Remarkably, this optimization of caudalization also results in the generation of MNs from pluripotent cells in as little as 14 d (ref. 25) . Similarly, by altering ventralizing signals, Du et al. 29 found that while high concentrations of smSHH can efficiently induce Olig2-expressing ventral progenitors, perhaps by bypassing endogenous feedback mechanisms, they also promote the specification of super-ventral progenitors that coexpress NK2 homeobox 2 (NKX2.2). These progenitors produce interneurons instead of MNs during the neurogenic phase. To limit the specification of NKX2.2-expressing progenitors and still promote the generation of Olig2-expressing progenitors, a cocktail of CHIR-99021 and SB431542 can be applied to dampen the effect of smSHH. This thereby reduces the most ventral NKX2.2-expressing progenitors induced by the highest concentration of smSHH and enriches for the Olig2 + Nkx2.2 − MN progenitors 29 . However, while a protocol to generate a pure population of MNs in the shortest amount of time may benefit manufacturing and screening, it remains unclear whether 'fast-tracked' hPSC-LMN maturation protocols accurately reflect overall cell physiology and maturation.
Rostral-caudal patterning of LMNs
It is clear that current MN differentiation protocols to do not give rise to more caudal types of neurons associated with lower limb function in animals and humans. The sequential expression of Cdx and Hox family members during development, referred to as colinearity 30 , dictates rostro-caudal identity along the hindbrain and spinal cord [30] [31] [32] . Early Hox family members associated with hindbrain, cervical-spinal and brachial-spinal origin are predominantly expressed in hPSCLMNs 24, 25, 33 25, 27 . hPSC-LMN protocols developed thus far do not generate cells that significantly express Hoxc9 through Hoxc12, which are associated with thoracic and lumbar identities 24, 27, 34 . However, very low expression of Hoxc9 and Hoxc10 is observed when retinoic acid is omitted during differentiation 26 . It may be possible that developmental FGF, TGFβ and retinoic acid signaling pathways could lead to refined protocols that enrich for lumbar spinal identities. FGF8 and growth differentiation factor 11 (GDF11) are highly expressed at caudal levels of the developing spinal cord and tail bud. Treatment with beads soaked in a high concentration of FGF8 induces lumbar MN identity in chick embryonic neural explants, and the addition of GDF11 significantly increases the expression of Hoxc9 and Hoxc10 (ref. 35) . The repression of retinoic acid receptor-γ (RARγ) signaling, both by small molecule inverse agonists and overexpression of dominant negative RARγ, increases the expression of posterior Hox genes in Xenopus embryos 36 . The specific activities of these lumbosacral morphogens are as yet untested in hPSC-LMNs, and additional or distinct signaling molecules may be required to modify Hox gene profiles.
In contrast to the protocols described above, the description of a common axial neuromesodermal progenitor (NMp) cell population in the caudal epiblast and tail bud of chicken 6 , mouse [37] [38] [39] and human 40 embryos has led investigators to develop protocols with distinct caudal LMN signatures. Following developmental evidence that neuroectodermal patterning specifies anterior neural fates 41 , bipotent NMps are unique in expressing both primordial neural and mesodermal signatures 42, 43 More work is necessary to compare these methods to one another (Fig. 2) , and the manipulation of lumbosacral morphogens described above may be similarly applicable in both differentiation strategies to achieve more caudal MN fates. To conclude, global anteroposterior axis representation in vitro will be needed in order to study hindlimbspecific onset commonly observed in mouse models of MN disease 45 or lower limb onset in ALS. . End of experiment (assay) based on last data presented. bFGF, basic fibroblast growth factor; FGF2, fibroblast growth factor 2; BDNF, brain-derived neurotropic factor; GDNF, glial cell line-derived neurotropic factor; CNTF, ciliary neurotropic factor; IGF-1, insulin-like growth factor 1; RA, retinoic acid; RAR, retinoic acid receptor; RXR, retinoid X receptor; SHH, sonic hedgehog; PMN, purmorphamine; EB, embryoid bodies. 46, 47 . Of these, HB9 is the most specific and is most often used as the primary method for identification of stem cell-derived LMNs. Analysis relying on this marker alone, however, could result in overestimation due to its expression in a subset of spinal interneuron subtypes, shown in mouse 48 . Further, HB9 is rapidly downregulated in a subset of brachial and lumbar limb-innervating LMNs and in preganglionic thoracic LMNs 49 . This in turn could paradoxically lead to an underestimation of LMNs in culture. Many studies therefore rely on Isl1 and Isl2 antigens or a combination of HB9 and an antibody that recognizes both Isl1 and Isl2, which is referred to as pan-MN staining 24 . Overall, LIM homeodomain proteins are eventually downregulated during development, making characterization of more mature LMNs challenging. SMI32, an antibody that recognizes LMN-enriched neurofilament heavy chain 50 facilitates morphological studies; however, neurofilament heavy chain expression in other cell types complicates analysis of mixed populations. Choline acetyltransferase is expressed by all cholinergic neurons, including LMNs; however, expression is weak in young stem cellderived LMNs and therefore it is not a reliable marker for young motor neurons, although it is a good marker for mature ones. Another cholinergic marker that labels both MN cell bodies and their cholinergic presynaptic specializations is vesicular acetylcholine transporter 51 . However, its expression, like that of choline acetyltransferase, is detectable only in more mature MNs. Nontraditional molecular markers such as microRNAs have promising utility for accurate MN identification in vitro, with miR-218 being recently identified to be the most MN-specific to date 52 . Strategies for generating and quantifying hPSC-LMN diversity (reviewed by Stifani 10 ) beyond pan-LMN markers are necessary to assess vulnerabilities specific to LMN subtypes in in vitro models of ALS 53 . Investigators have begun to characterize hPSC-LMNs as limb-innervating lateral motor column (LMC) and axial muscleinnervating medial motor column (MMC) on the basis of transcriptional profiles observed in developing mouse embryos 54 . Forkhead box P1 (FOXP1) and Aladh1a2 (also referred to as retinoic acid dehydrogenase 2 (RALDH2)) 24,55 characterize LMC-innervating LMNs and limb homeobox containing 3 (LHX3) characterize the MMC in vivo 56 . Fate specification studies have also shown that high expression of FOXP1 is required for LMC and preganglionic motor column specification 55 . Studies that overexpress this transcription factor in mES cell-derived MNs have shown successful innervation of limb skeletal muscle when implanted into the spinal cord of developing chick embryos 57 . While most researchers 25, 33, 58 have reported mixed populations of LMC and MMC subtypes in human hPSC-LMNs in vitro, Patani et al. 26 showed an enriched MMC identity with the omission of retinoids from the differentiation medium, and Amoroso et al. 24 showed an enhanced LMC fate with the combined use of the smSHH and purmorphamine. More constitutive column-specific markers are needed, as LHX3, for example, is expressed by all MNs early in development, but then LHX3 is maintained specifically in MMC subtypes, which ultimately downregulate LHX3 when they mature in vivo 56, 59 . In addition, hypaxial motor column subtypes remain poorly defined in vitro.
Transcriptional molecular profiling
Genome-wide assessment of gene expression by RNA or protein profiles can provide a global, systems-level measure of LMN maturity. Cross-sectional comparisons between disease and control hPSC-LMNs are routinely performed to gain insight into the ALS-induced disruptions to gene expression 60, 61 . However, the fidelity and thus relevance of these models to molecular events occurring in mature LMNs in the human body remains unclear. This is due to the lack of comparisons between in vitro-derived hPSC-LMNs and in vivo-derived embryonic, fetal, adult and aged LMNs. Studies that have compared the transcriptome of iPSC-derived neural tissue to counterparts in vivo add to the consensus that iPSC-derived tissues resemble an embryonic state 62, 63 . However, a prolonged time in culture advances their progression toward a mature molecular signature to some extent 64 . A more recent study leverages transcriptomic data from the Allen Brainspan Atlas to include human brain specimens ranging from embryonic to aged adult stages 63 . Employing several methods to compare mRNA expression profiles with stem cell and progenitorderived neurons, the authors conclude that despite several months of post-differentiation culture, in vitro-differentiated neural cells are restricted to an embryonic or fetal-like state. This obstacle to neural maturation may be due to a technical lack of understanding of the key elements in tissue culture that would be needed to produce mature cells that are transcriptionally equivalent to their in vivo counterparts. Alternatively, this obstacle may also be due to the protracted time course of human development. Whether this obstacle to maturity also holds true for LMN cultures as well remains to be seen. Investigations comparing in vitro LMN cultures to in vivo LMNs during finely resolved developmental time points using genome-wide assays such as RNA sequencing and mass spectrometry promise to provide greater insight into transcriptional and post-transcriptional mechanisms regulating LMN maturity. This could in turn guide in vitro culturing strategies to promote maturation in hPSC-LMNs and provide deeper understanding of MN development and disease. 60, 61, 65, 66 . In early stages, iPSC-derived neurons develop voltage-gated K + and Na + ion channel currents that are sufficient to generate induced action potentials. Interestingly, the nature of these action potentials develops over time (Fig. 3) 67 . Initially, induced action potentials show relatively slow depolarization and repolarization, correlating with small Na + and K + currents. With maturation, these action potentials become sharper as Na + and K + currents increase, but very few hPSC-LMNs develop the ability to fire trains of action potentials comparable to those in adult cells in vivo. Transition from simply being able to fire induced action potentials to generating spontaneous activity requires the development of intrinsic (for example, sufficiently polarized resting membrane potentials) and extrinsic (for example, synapse formation) properties that may indicate an even greater level of maturation. Even with extended time in culture, hPSC-LMNs exhibit intrinsic properties and action potential dynamics that are broadly consistent with rodent LMNs at an embryonic developmental stage 68 . Specifically, this is indicated by inadequately polarized resting membrane potentials and by input resistances 5-to 20-fold higher than those in adult in vivo counterparts. Functionally, this produces neurons that are artificially hyperexcitable, but with limited ability to spontaneously generate action potentials. Another important intrinsic property is the membrane capacitance, which is defined as the ability to store an amount of charge across the membrane for a given voltage. As the membrane capacitance is proportional to the cell surface area, it is both an important parameter for excitability and used as a crude measure for the morphological complexity of neurons. In accordance with inadequate polarization and spontaneous activity, hPSC-LMNs maintain significantly lower capacitance 69 than is observed in vivo 70 .
In addition to embryonic-like intrinsic properties, hPSC-LMNs show little ability to generate synapses, a component of a neuron's function that is critical, as they allow the propagation of electrical signals from one neuron to the next. Further, network-driven spontaneous action potential activity is thought to drive LMN maturation and functional integration into the spinal cord 71 . By contrast, there is a distinct lack of network-level activity in hPSC-LMNs, which may be as a consequence of a lack of appropriate input neurons and further confounded by the depolarized resting membrane potentials. Coculture with primary cortical rodent astrocytes results in a substantial improvement in both network-level spontaneous activity and basic intrinsic properties in hPSC-LMNs 69 . The precise role of the primary astrocytes in this case is unknown; however, primary astrocyte coculture elicits increased synaptogenesis and hyperpolarized resting membrane potentials in iPSC-derived neuronal cultures 67 .
The search for specific LMN reporters Cell surface antigens and fluorescent reporters are powerful tools for purification and analysis of LMNs in living culture systems. Several groups have generated stably integrated HB9øgreen fluorescent protein (GFP) transgenic reporter cell lines 72 . However, the utility of HB9 reporters is limited by the variable levels of GFP expression in individual cell lines and only partial overlap between GFP and other LMN markers, likely due to positional effects of transgene integration and lack of complete promoter regions for HB9 that would give more specificity. Furthermore, HB9 reporters are downregulated over the course of maturation, complicating long-term live imaging of LMN and analysis of LMN maturation and survival.
New fluorescent reporters based on expression from Isl1, choline acetyltransferase and vesicular acetylcholine transporter promoters are being pursued for a more developmentally stable expression system. However, relatively low expression and high intracellular turnover can result in limited reporter signal. To circumvent these issues, new dual reporter constructs are being developed that combine MN-specific expression of Cre recombinase with a Cre-activated reporter system. In this system, Cre recombinase is expressed under the weak MN-specific promoter; meanwhile, a second construct is inserted into a safe-harbor genomic site. The latter includes a strong promoter downstream of a loxP-flanked transcriptional stop site that will ultimately drive a fluorescent reporter. When both constructs are introduced into cells, activity of the endogenous MN-specific promoter generates small amounts of Cre, which in turn acts to excise the transcriptional stop site, thereby allowing the strong promoter to permanently turn on the reporter gene in the MN. While this approach will amplify the expression of reporters in MNs and circumvent reporter downregulation during long-term maturation studies, it will also magnify the lack of specificity associated with many currently used MN promoters. It will therefore be critical to transition from randomly integrated transgenic constructs to knock-ins of Cre recombinase into MN-specific genes. Further refinement could be achieved by the use of tamoxifen-regulated Cre fused to a modified fragment of the estrogen receptor (Cre-ERT2) instead of basic Cre. While the efficiency of recombination and MN labeling might be decreased, the ability to pulse-label MNs will provide a much-needed tool to study long-term MN survival by eliminating the confounding effects of ongoing MN genesis in human cultures 73 . In addition to these efforts to improve the available repertoire of fluorescent MN reporters, the identification or engineering of new MN-specific cell surface antigens for magnetically assisted cell sorting protocols will facilitate the purification of MNs from mixed cultures with less ) have not yet been generated from iPSCs and may be required for functional NMJ formation in vitro. SMI32 is a neurofilament heavy chain epitope; Isl1, Islet-1; GFAP, glial fibrillary acidic protein; SMA, smooth muscle actin.
npg r e v i e w mechanical stress than traditional flow cytometry approaches. While primary MNs have been successfully purified from embryonic rat spinal cord using an antibody to the nerve growth factor receptor p75 (ref. 74) , identification of more specific and developmentally stable surface antigens will be required for efficient purification of human iPSC-derived MNs.
Completing the neuromuscular circuit
As cell type-specific derivation methods evolve, opportunities to recreate the entire neuromuscular circuit in vitro are underway (Fig. 4) 75 .
Completely patient-derived NMJ models may now be in reach through the combination of LMN, astrocyte 77, 78 and myofiber 79 differentiation schemes (Fig. 4) . It is worth noting that additional cell types, including UMNs, Schwann cells, microglia, oligodendrocytes, interneurons, monocytes, endothelial cells and others, also contribute to neuromuscular circuit function and could be relevant in coculture systems. Moreover, the potential influence of the regional identity of astrocytes in the spinal cord 80 , presence of specific interneuron subtypes, and functional interaction with myofibers present unique challenges compared to those of other neural systems in the CNS. Though these coculture methods strive to bring us closer to the complexity inherent in all multicellular organisms, two-dimensional culture systems are far from the physiological milieu of the spinal cord. Consequently, microfluidic organ-on-a-chip systems are now being developed whereby different cell types can be compartmentalized and grown juxtaposed in a three-dimensional environment. These systems (reviewed by Bhatia and Ingber 81 ) require very low volumes of media and allow enhanced control of cell-cell contact and paracrine conditioning effects. If these systems could be adapted for LMN differentiation, they might further enhance LMN maturity and function.
UMN developmental mechanisms and directed differentiation
Although hPSCs have the theoretical potential to generate large quantities of UMNs in vitro, existing hPSC protocols are not yet capable of generating specific classes, types or subtypes of neocortical projection neurons 82 . Though much more needs to be done to achieve bona fide UMN differentiation from PSCs, there has been substantial progress in our understanding of stepwise developmental molecular programs that direct neocortical projection neurons and their subtypes in mice [83] [84] [85] . Analyzing existing UMN derivation protocols with these newly discovered characteristics has revealed heterogeneous, neocortical-like neurons that are immature and stalled at a stage resembling mid-embryonic differentiation in vivo 86 . By applying lessons from initial mouse PSC and hPSC telencephalic, cortical neuron differentiation studies to emerging molecular understanding of UMN development described here, it is now practical to design more refined routes to promote UMN-specific differentiation schemes to benefit the study of UMN degeneration observed in ALS.
Telencephalic to neocortical development
Modeling UMNs for ALS research is not as straightforward as it has sometimes been presented, since there is immense diversity of cerebral cortex projection neurons (of which UMNs are one relatively rare and minor subtype) and ALS does not promiscuously affect the broad population of cortical projection neurons, either in humans or in ALS model mice. The diversity contained within the adult neocortex and among UMNs progressively emerges during an extended course of development. UMNs are a subtype of the neocortical projection neuron subclass of corticofugal projection neurons (from the Latin, "traveling away from the cortex"), and they are among the very first neurons to populate the embryonic neocortex. Corticofugal projection neurons are classified by their distinct axonal projections to multiple targets inside or outside the neocortex 83, 87, 88 ( Fig. 5) . In an analogous situation to 'default' neural induction, the rostral specification of neural tube progenitors occurs largely in the absence of caudally derived spinal cord morphogens (for example, FGFs and retinoids). To a similar effect in vitro, the first successful telencephalic differentiation from mES cells involved removal of serum that contains multiple caudalizing morphogens, as well as treatment with Wnt and Nodal antagonists 89 . Default rostral differentiation now constitutes the first step of most protocols of telencephalic differentiation by PSCs 82, 90 . Importantly, the identity of early rostral npg r e v i e w Figure 6 Cell-extrinsic and cell-intrinsic factors regulate the development of corticofugal projection neurons in sequential, 'nested' stages of differentiation. (1) 'Default' neural and rostral differentiation occurs by repression of alternative signaling pathways induced by multiple morphogens (for example, Noggin inhibits BMP signaling during neural plate formation at ~E3.5-E6.5 in mice; cortical progenitors require low or absent expression of caudalizing retinoids (RA) and ventralizing SHH at ~E6.5-E8.5). (2) The dorsal aspect of the telencephalon is called the pallium; it gives rise to the neocortex. In contrast, the ventral telencephalon is called the subpallium. The delineation of these two telencephalic progenitor domains occurs between ~E8.5 and ~E10.5. (3) During corticogenesis, beginning at ~E10.5 in mice, diverse cortical projection neuron classes, types and subtypes are sequentially generated from cortical progenitors. These projection neurons become refined with continued maturation through postnatal ages. progenitors, characterized by the specific expression of forkhead box G1 (FoxG1) 91, 92 , is reinforced by cell-intrinsic expression of transcriptional regulators, including orthodenticle homeobox 2 (Otx2), which demarcates the midbrain-hindbrain boundary and is required for early specification of forebrain and midbrain 93 .
A series of steps is necessary to generate UMNs during development, making their generation from PSCs more complex than that of LMNs. The dorsal forebrain or telencephalon, which is called the pallium and is roughly equivalent to the neocortex (hereafter "cortex"), ultimately gives rise to all (neo)cortical (roughly equivalent to cerebral cortex) projection neurons and is developmentally specified in the absence of SHH signaling and in the presence of Wnts and BMPs 12, 94 . Antagonism of SHH signaling can be exploited to enrich the differentiation of mES cells to dorsal, cortical fates 95 . This approach, by Gaspard and colleagues, is widely used for investigations of mouse corticogenesis in vitro 94 and has been adapted to hPSCs 96, 97 . In contrast to mouse PSC derivation, however, SHH antagonism is reported not to similarly enhance the generation of human cortical progenitors, which seem more dependent on timing of retinoid signaling for cortical enrichment 97, 98 . Thus, making some type of 'generic cortical neuron' appears straightforward, but these are not UMNs sufficient for ALS modeling, nor are they specific in their identity.
There is a progressive set of cross-repressive events that sequentially distinguishes projection neuron subtypes, in particular UMNs. Later in mouse development, cortex-restricted transcription factor Pax6 promotes cortical fate in part by reciprocal and robust cross-repression of GS homeobox 2 (Gsh2), whose expression is restricted to the subpallium 99 , or ventral telencephalon. In a complementary manner to Pax6, Sox6 is also required for the proper specification of cortical progenitors, and its absence results in mis-specification, with ectopic expression of ventral genes including Achaete-Scute family basic helix-loop-helix transcription factor 1 (Ascl1) 100 . Sox2 is also required for proper early cortical differentiation 101, 102 (reviewed by Georgala et al. 103 ), and later LIM homeobox 2 (Lhx2) is required for proper neocortical progenitor development by embryonic day (E) 10.5 in the mouse 104, 105 . Thus, multiple transcriptional regulators expressed in the cortex (Pax6, Sox6, Lhx2 and Sox2) ultimately enable proper differentiation of neocortical progenitors, which increasingly relies on cell-intrinsic mechanisms of neocortical development (Fig. 6) . That said, their sequence and dose matter critically, not just their expression.
The specification, postmitotic differentiation, axon guidance and axon pruning of UMNs are largely controlled by the transcriptional activities of FEZ family zinc finger 2 (Fezf2), COUP-TF interacting protein 2 (Ctip2) (also called B-cell CLL/lymphoma 11B, or BCL11B) and Otx1 (refs. 106-108) . Although these three transcription factors are initially expressed both by UMNs and by corticothalamic projection neurons at lower doses, the dose and timing of their expression controls UMN specificity. First, Fezf2 is necessary for npg r e v i e w the specification of UMN and the broader set of related subcerebral projection neurons, but not of corticothalamic projection neurons (although they develop abnormally in the absence of Fezf2). In the absence of Fezf2, downstream Ctip2 transcription factor expression is lost, and prospective UMNs instead differentiate into deep-layer commissural neurons and corticothalamic projection neurons 109 . Second, Ctip2 is critical for the postmitotic development of UMNs and other subcerebral projection neurons, and, in its absence, UMNs do not project to the spinal cord and show additional defects in axon outgrowth, fasciculation and guidance. Third, Otx1 is specifically expressed by postmitotic UMNs and directs pruning of subcerebral projection neuron axons during late postnatal maturation 110 . Together, Fezf2, Ctip2 and Otx1 are essential for the proper differentiation of UMNs and other subcerebral projection neurons, and the specifics of UMN development might be critical to appropriate ALS modeling.
Overcoming deficits in directed UMN differentiation Observations by C.S. and J.D.M. 86 describe distinct deficits of mES cell-derived cortical-like progenitors and neocortical-like neurons that are likely shared by those derived from human iPSCs; however, direct species comparisons are lacking. Current mES cell-derived cortical-like progenitors are more heterogeneous than their in vivo counterparts and seemingly include many incorrectly specified progenitors, indicative of both cortical and general forebrain fates. Also, current mES cell-derived neurons are not uniformly or completely mature, and even the most advanced display crucial hallmarks of early maturation roughly equivalent to those of mouse neocortical neurons in vivo at E16.5-E18.5. Specifically, these neurons express multiple transcription regulators (for example, T-box, brain 1 (Tbr1), Ctip2 and SATB homeobox 2 (Satb2)), which are consistent with immature neocortical projection neuron expression signatures at a stage equivalent to mid-corticogenesis in vivo. Finally, these stalled neocortical-like neurons appropriately express certain postmitotic regulators of area-specific differentiation (such as COUP transcription factor 1 (CoupTF1) and basic helix-loop-helix domain containing, class B5 (Bhlhb5), which may indicate deficits in area-specific cortical differentiation. These regulators specify both motor and visual cortical neurons, the latter of which are not involved in ALS. It is clear that current UMN derivation methods are in nascent stages in vitro. Multiple cell-intrinsic and cell-extrinsic processes, however, including focal chromatin remodeling, post-translational modifications of transcriptional regulators, cell-cell contacts and paracrine molecular signaling, regulate the stepwise generation of UMNs in vivo. These provide promising leads that remain largely untested in hPSC-derived cultures. More layers of control might be required to generate reasonable UMNs from PSCs for modeling. During the sequential generation of neocortical projection neuron subtypes, the refinement and maturation of neocortical progenitors and postmitotic neurons are progressively shaped by epigenetic changes, including histone remodeling and methylation, DNA methylation, and regulation by noncoding RNA 111 . The roles of histone deacetylases have been identified in multiple forebrain cell types, including retinal subtypes 112 and cortical neurons 111, 113 . A number of neocortical subtype-specific transcriptional regulators (for example, Ctip2, Satb2, Ski) can directly interact with chromatin remodeling enzymes, implicating epigenetic mechanisms of cortical subtype specification and maturation. In addition, post-translational modifications (for example, phosphorylation and sumoylation) of critical transcription factors might be important for the regulation of subtype specification and possibly for directed UMN differentiation and maturation. The sumoylation of Ctip2, shown in hippocampal neurons 114 , and Satb2, shown in non-neocortical cells 115 , might regulate precise subtype specification in the neocortex. Thus, these post-translational modifications of critical transcriptional regulators are potentially useful for the assessment of appropriate UMN specification from pluripotent stem cells.
Though established monolayer protocols offer advantages for highthroughput optimization and therapeutic screening, the absence of three-dimensional cell-cell interactions in monolayer culture might impede subtype-specific refinements. Notch signaling is one of the best-studied mechanisms of cell-cell signaling in the cortex. It is particularly relevant to directed differentiation, given its longstanding roles in delineating distinct identities in related cell types 116 , including cortical migration 117 , neurogenesis 118 and asymmetric cell division 119 . Consistent with this hypothesis, an established embryoid body protocol of forebrain differentiation generates neurons with seemingly reduced expression of distinct cortical subtype markers 120, 121 . Despite the apparent benefits of embryoid body culture, distinct deficits in neuronal laminar organization indicate that cell-cell contacts are either incompletely replicated or insufficient in embryoid body culture without additional factors and/or regulatory mechanisms.
Further complicating UMN modeling, numerous cell-extrinsic factors are required for cortical neuron development in vivo (reviewed by Tiberi et al. 94 ). Among these factors, several are subtype-specific. First, the well-studied endocannabinoid signaling pathway has been recently identified as critical for maintenance of proper UMN subtype 122 . Second, insulin-like growth factor 1 (IGF-1) specifically activates and enhances rate of extension of UMN axons 123 . Moreover, several other factors, including IGF-2 and BDNF, enhance survival of cultured UMN 124 . Finally, mutant mice lacking choroid plexus have a reduction in UMNs 125 . This phenotype is striking because it suggests that one or more of the many growth factors secreted in the cerebrospinal fluid (for example, IGF-1, IGF-2) are critical for molecular refinement of UMN identity 126 . As in enhanced LMN generation protocols, the concentration and timing of these and nonsubtype-specific factors such as FGF8 (ref. 120 ) and retinoids 97 may also benefit from high-throughput optimization studies to increase UMN generation efficiency and function in vitro.
Methods to accelerate MN maturation and aging in vitro
Both in human development and in vitro, LMNs and UMNs require substantially more time for neurogenesis and maturation to occur than their murine counterparts. Aside from apparent challenges such as increased time in culture, study length and cost, the ability of in vitro hPSC-derived cells to exhibit mature, native functional properties is crucial for accurate in vitro modeling of adult-onset diseases. An interesting approach for artificially accelerating the aging process genetically manipulates iPSC-derived neurons to express progerin, a mutated form of lamin A, which causes the premature aging disease progeria 127 . Upon progerin overexpression, iPSC-derived dopaminergic neurons exhibit age-associated changes; however, the nonage-related effects of artificial lamin A expression in neurons is unknown. By interfering with Notch signaling, small molecule γ-secretase inhibitors, namely DAPT (N-[(3,5-difluorophenyl)acetyl]-l-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester) and compound E, have been shown to accelerate neuronal differentiation by delaying the cell cycle transition from G1 to S phase long enough to commit neurons to neurogenesis 128, 129 . These inhibitors have been shown to be effective in hPSC-LMN protocols as well 25 . While these compounds have proven useful in promoting cell cycle exit, the consequences of this treatment for MN diversity is unexplored. As different MN subtype npg r e v i e w fates emerge at distinct developmental time points in vivo, premature cell cycle exit could obstruct later MN subtype programs.
An alternative method of generating human MNs in vitro is described as induced MNs 28 . This process circumvents reprogramming to pluripotency by directly converting patient somatic cells to MNs through transgenic expression of transcription factors that drive MN differentiation. By avoiding the epigenetic 'reset' that occurs during reprogramming to pluripotency 130 , this approach has been shown to maintain age-related epigenetic signatures accrued over the lifetime of the patient 131 . Induced MNs display age-related cellular defects not observed in hPSC-MN approaches. However, these approaches are challenged by genomic instability resulting from increased somatic cell expansion requirements, as well as deficient MN maturation in vitro.
It is widely accepted that the maturation status of iPSC-derived cells remains a hurdle to the field of regenerative medicine at large, and yet it remains underexplored in humans 4 . The ability to harness cell signaling to promote maturation in vitro rests on increased understanding of anatomical, molecular and electrophysiological data from fetal, adult and aged human spinal postmortem tissue. Projects such as the Allen BrainSpan Atlas provide valuable templates to guide anatomical-and genomic-level evaluation of native human MN maturation and aging. However, detailed functional data on human MNs are lacking, and therefore comparative evaluation of functional maturity relies largely on the characterization of other mammalian species, often at a cost to fidelity.
Can we currently model ALS using iPSC-derived MNs?
Only about 10% of ALS cases are inherited (termed familial ALS, or fALS). A common strategy for studying diseases with this familial signature is to interrogate specific causal gene mutations in this population for disease mechanisms that can then be applied to the patient population as a whole. Traditional murine transgenic models of ALS have been extensively studied (reviewed by Swarup and Julien 132 ); however, treatments developed using these models have not been effective in human trials, indicating a need for the study of human tissue. Human LMNs differentiated from iPSCs that had been generated from an ALS patient carrying a mutation in the superoxide dismutase 1 (SOD1) gene 133 provided the groundwork for subsequent fALS disease modeling studies in vitro. More recently, separate iPSC studies from SOD1 A4V mutants, an aggressive form of fALS, have yielded distinct phenotypes. Significant Isl1 + cell loss, reduced neuronal soma size and increased apoptotic cells were observed in one study with hPSC-LMNs cultured for 30 d after differentiation. Comparative RNA-sequencing of genetically corrected isogenic controls revealed distinct mitochondrial and transport dysfunction in the uncorrected lines 60 . Meanwhile, another group using a similar isogenically controlled approach showed that mutant SOD1 binds to neurofilament mRNA and leads to neurite swelling and degeneration, but that mutant SOD1 does not induce cell death in vitro 65 .
ALS research progressed with the recent discovery of a mutation in the chromosome 9 open reading frame 72 (C9orf72) gene 134 . This mutation, involving an intronic hexanucleotide repeat expansion, was identified as the most common form of familial ALS and frontotemporal dementia, accounting for approximately 40% of familial and 8-10% of sporadic cases 134, 135 . Unlike SOD1 transgenic mouse models, C9orf72 mutant mice have not yet shown diseasespecific MN loss in vivo. To study the effects of C9orf72 mutations on human tissue, investigators have generated iPSCs from patients with such mutations. In contrast to SOD1 mutant studies, three recent investigations with C9orf72 mutant hPSC-LMNs report no overt LMN loss in vitro 61, 66, 136 . These hPSC-MN cultures do, however, exhibit intranuclear C9orf72 repeat-containing RNA foci detected by fluorescence in situ hybridization, indicating a disease-specific physiological phenotype independent of overt cell death. These foci can be partially resolved using antisense oligonucleotides that target the hexanucleotide expansion 61, 136 . Additionally, the hPSC-LMN cultures derived from C9orf72 patients display RNA binding protein interactions and repeat-associated non-ATG (RAN) proteins, along with a high susceptibility to glutamate-mediated excitotoxicity 136 .
An important phenotypic distinction between fALS disease modeling studies lies in neuronal excitability. Altered LMN excitability has long been associated with ALS pathogenesis in rodent models [137] [138] [139] and patients 140, 141 , and mutant SOD1 and C9orf72 patient-derived hPSC-LMNs also demonstrate a hyperexcitable state. In these experiments, the hyperexcitability phenotype was shown to be effectively attenuated by the small molecule retigabine, an activator of Kv7 currents 69 . In contrast, another group noted a hypoexcitable state in C9orf72-derived cultures 61 . As a result, hPSC-LMN membrane excitability phenotypes in relation to ALS have remained an area of dispute. Recently, however, temporal analysis studies using iPSCs derived from both familial C9orf72 and TAR DNA-binding protein (TARDBP) mutants have demonstrated that both hyper-and hypoexcitable phenotypes exist at distinct time points of culture maintenance 66 . Specific subsets of C9orf72 and TARDBP patient-derived LMNs classified according to their firing state exhibit a hyperexcitable state early during maturation, followed by a hypoexcitable state after 9 weeks in culture, with a loss of both voltage-activated Na + and K + currents. fALS patient-derived hPSC-LMNs also show progressive loss of synaptic activity, in accordance with ALS patient data and rodent models 66 . While this study seems to have resolved the inconsistencies between competing functional phenotypes, discrepancies in hPSC-LMN vulnerability in vitro are still confounded by differing hPSC-LMN derivation and culture techniques between investigators.
Altered excitability in LMNs as evidenced by these studies offers a plausible role in ALS disease progression. However, further experimental support of these findings is required to determine whether reported phenotypes are pathogenic or simply homeostatic responses to culture conditions, particularly a reduced synaptic input. To add to this complex dynamic, recently published electrophysiological studies of SOD1 G93A mouse LMNs demonstrate that the subclass of immediate-firing LMNs that innervate slow-contracting fibers (S-type MNs), which do not degenerate in the SOD1 G93A mouse model of ALS, show hyperexcitability while the vulnerable subclass of delayed firing LMNs that innervate fast-contracting fibers (F-type MNs) do not show altered excitability 142, 143 . These data further highlight the need for an enhanced grasp of the specific cellular identity of LMNs in vitro to correctly establish whether altered LMN excitability contributes to ALS disease progression.
The contribution of UMN hyperexcitability to the pathogenesis of ALS is an area of intense investigation in both clinical and laboratorial settings. Studies in transgenic ALS mice have observed evidence of hyperexcitable UMNs that precede the onset of motor symptoms and LMN degeneration 144 . The selective suppression of mutant SOD1 in the motor cortex of SOD1 G93A ALS mice can delay overall disease onset 145 . In the clinic, the presentation of cortical hyperexcitability is well documented 146 (reviewed by Bae et al. 147 ). Though retigabine is effective in reducing excitability in hPSC-derived LMNs, its efficacy remains largely untested in newer UMN derivation protocols. Elucidating UMN-specific mechanisms in ALS in vivo and in vitro will be crucial for the field moving forward. npg r e v i e w Conclusion While the complete recapitulation of human ALS pathology in vitro is admittedly a lofty prospect, these studies demonstrate the utility of disease modeling technology available today. As these applications are developed across different laboratories, it is crucial that stringent criteria emerge to enable adequate comparison of results among investigations. These include maturation, molecular characterization and electrical and transcriptional function of iPSC-derived MNs, as well as their interaction with other cell types in vitro. However, the relevance of these models will ultimately be determined by their ability to translate to real treatment for patients. Though functional and molecular phenotypes associated with ALS patient-derived hPSCMNs have been observed, successful treatments in vitro have yet to meet this ultimate goal. Critically, the need to address population diversity in these models is becoming more apparent. While early proof-of-concept studies represent only up to a few patients, a requirement that disease phenotypes be supported by a more substantial sample size is being addressed. In the short term, increasing sample size to 4-10 individuals will have an appreciable effect on the strength of observed ALS-related phenotypes. Beyond this, efforts underway to generate iPSCs from large patient populations will allow future studies to more adequately represent diverse patient pools. To capitalize on these large iPSC banks, a single, unified method for studying human MNs ex vivo may help to accelerate therapy development by enabling joint efforts that can capitalize on diverse strengths in the research community. However, there is still work to be done in defining what that method should be, given the rapid developments in the field of neural differentiation at the present time.
In spite of these uncertainties, it is clear that progress in modeling ALS and, in turn, our understanding of this terminal disease rests on the replication of phenotypes across investigators, maturation of cultures to emulate aged tissue, and enhanced methods to assess experimental data generated from patient-derived cultures. With collaborative approaches among researchers aligned in the interests of human biology and improving patient care, these objectives are in reach.
